Sign In
Buy ETON
$27.61
+0.210 (+0.766%)
At Close: Jun 03, 2026
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
09:00am, Tuesday, 18'th Mar 2025
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
06:50am, Tuesday, 18'th Mar 2025
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
06:50am, Friday, 14'th Mar 2025
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 -
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
10:00am, Tuesday, 04'th Mar 2025
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
06:50am, Tuesday, 04'th Mar 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
06:50am, Monday, 03'rd Mar 2025
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going
09:51am, Wednesday, 12'th Feb 2025
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
06:50am, Friday, 07'th Feb 2025
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval –
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
06:50am, Thursday, 06'th Feb 2025
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
New Strong Buy Stocks for January 28th
07:21am, Tuesday, 28'th Jan 2025
PBPB, BBCP, BAK, NVAX and ETON have been added to the Zacks Rank #1 (Strong Buy) List on January 28, 2024.
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?
05:21am, Friday, 24'th Jan 2025
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
06:50am, Friday, 03'rd Jan 2025
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
06:50am, Friday, 20'th Dec 2024
DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
06:50am, Tuesday, 03'rd Dec 2024
DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
06:50am, Monday, 25'th Nov 2024
DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercial
